Last reviewed · How we verify
Foradil P 24µg
Foradil P 24µg is a long-acting beta2-adrenergic receptor agonist (LABA) used to control and prevent bronchospasm in patients with asthma and COPD.
Foradil P 24µg is a long-acting beta2-adrenergic receptor agonist (LABA) used to control and prevent bronchospasm in patients with asthma and COPD. Used for Asthma, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Foradil P 24µg |
|---|---|
| Sponsor | MEDA Pharma GmbH & Co. KG |
| Drug class | LABA |
| Target | beta2-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
It works by stimulating the beta2-adrenergic receptors in the lungs, leading to bronchodilation and improved airflow. This results in improved lung function and symptoms in patients with asthma and COPD.
Approved indications
- Asthma
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Tachycardia
- Palpitations
- Headache
- Dysphonia
- Muscle cramps
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Foradil P 24µg CI brief — competitive landscape report
- Foradil P 24µg updates RSS · CI watch RSS
- MEDA Pharma GmbH & Co. KG portfolio CI